Navigation Links
TPI Receives GMP Certification for JCM Facility
Date:1/19/2012

on several underlying basic principles: 1) Clearly defined manufacturing processes that are controlled with critical processes validated to ensure consistency and compliance with specifications during the production; 2) Good Documentation Practices; 3) Operators are trained to carry out and document procedures; 4) Records are made, manually or by instruments, during manufacture that demonstrate that all the steps required by the defined procedures and instructions were carried out and that ensure the quantity and quality of the drug; 5) Records of manufacture and distribution that trace the complete history of a batch are retained in a comprehensible and accessible form. 6) The distribution of the drugs minimizes any risk to their quality; 7) A system is available for recalling any batch of drug from sale; 8) Complaints about marketed drugs are examined, the causes of quality defects are investigated, and appropriate measures are taken with respect to the defective drugs and to prevent recurrence.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit: http://www.tianyinpharma.com, or email ir@tpi.asia
Tel: +86-28-8551-6696 (Chengdu, China)
     +86-134-3655-0011 (China)

Address:
Tianyin Pharmaceutical
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
C
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
2. Life Technologies Receives AFNOR Validation for Tests Designed to Detect Listeria Contamination in Food Samples
3. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
4. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
5. BioNeutral Group Receives $400,000 in Equity Financing
6. Pacific Meso Center Receives Generous Donation to First Free-Standing Mesothelioma Research Laboratory in Los Angeles
7. Intimate Bridge 2 Conception, Inc. Receives $4.3M
8. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
9. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
10. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
11. Watsons Generic Yaz(R) Receives FDA Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE MKT: ... of biosimilar therapeutics, today announced that it will be ... Marquis on March 2 nd at 3pm PST. Patrick ... a panel discussing the current state of the biosimilar ... . For more information on CALBIO ...
(Date:2/26/2015)... NEW YORK , Feb. 26, 2015 ... commenced Factual Stock Report coverage on MabVax Therapeutics ... Inc. (MBVX) is a clinical stage biotechnology company focused ... address unmet medical needs in the treatment of cancer. ... products based on the protective immune responses generated by ...
(Date:2/26/2015)... , Feb. 26, 2015   Regulus Therapeutics ... company leading the discovery and development of innovative medicines ... , Ph.D., President and Chief Executive Officer of Regulus, ... Company 35 th Annual Healthcare Conference on Wednesday, ... is being held at the Boston Marriott Copley Place.  ...
(Date:2/26/2015)... 2015  NuGene International, Inc. ("NuGene") (OTCQB: NUGN), ... and hair rejuvenation, has announced that it has ... for investor relations and strategic communications. ... and diversification strategies – and we need to ... stated Ali Kharazmi CEO of NuGene when announcing ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3
... Company, FRAZER, Pa., Feb. 8 Cephalon, Inc., ... Counsel &,Secretary, John E. Osborn, has decided to resign ... has agreed to remain as an advisor,to the company ... been an invaluable member of our senior executive team ...
... REDWOOD CITY, Calif., Feb. 8 Genomic Health,Inc. (Nasdaq: ... Health,s,President and Chief Operations Officer, will present at the ... Feb. 12, 2008 at 10:15 a.m. Eastern,Time., To ... visit the Investor Relations section of Genomic Health,s,website at ...
... InterMune, Inc.,(Nasdaq: ITMN ) today announced results from operations ... company also provided 2008,financial guidance and milestones for its key ... InterMune reported a net loss for the fourth quarter of ... net loss of $21.5 million, or,$0.64 per share, in the ...
Cached Biology Technology:Cephalon General Counsel John E. Osborn to Resign Position 2Cephalon General Counsel John E. Osborn to Resign Position 3InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 2InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 3InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 4InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 5InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 6InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 7InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 8InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 9InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 10InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 11
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... SAN DIEGO , Jan. 26, 2015   Epic ... treatment of cancer, today announced that Murali Prahalad , ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, ... Mountain View, Calif. on January 26-28, ... entitled, "CTCs Come of Age as Biomarkers." Last year, Epic ...
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... date of 130 North American tree species concludes that ... northward by hundreds of kilometers and shrink the ranges ... McKenney of the Canadian Forest Service and his colleagues, ... McKenneys study is based on an extensive data-gathering effort ...
... Trust researchers have identified a key gene involved in the ... mostly women. The lead researcher behind the study has called ... to further study the underlying causes of the disease. ... autoimmune disease which frequently causes skin rash, joint pains and ...
... able to differentiate metastatic cancer cells from normal cells ... softness of the cells. The study, published Dec. ... journal Nature Nanotechnology, represents one of the first times ... cancer patients and apply nanotechnology to analyze them and ...
Cached Biology News:Climate change predicted to drive trees northward 2Lupus gene finding prompts call for more DNA samples 2Using nanotechnology, UCLA researchers discover cancer cells 'feel' much softer than normal cells 2Using nanotechnology, UCLA researchers discover cancer cells 'feel' much softer than normal cells 3Using nanotechnology, UCLA researchers discover cancer cells 'feel' much softer than normal cells 4
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Anti-Human alpha2-Antiplasmin Purified (Polyclonal) (goat IgG)...
Volume adapter mounts on top of the 96 well FiltrEX filter plate and allows larger volumes (1mL) to be applied to each well in a filter plate. Adapters are nonsterile....
... The Mini-PROTEAN 3 Dodeca cell with multi-casting chamber ... up to 12 mini format handcast (8.3 x ... gels. The cell requires 3.4-4.4 L of buffer ... coil that attaches to an external refrigerated circulator ...
Biology Products: